Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Parallel visualization of multiple protein complexes in individual cells in tumor tissue.

Leuchowius KJ, Clausson CM, Grannas K, Erbilgin Y, Botling J, Zieba A, Landegren U, Söderberg O.

Mol Cell Proteomics. 2013 Jun;12(6):1563-71. doi: 10.1074/mcp.O112.023374.

2.

Proximity probing assays for simultaneous visualization of protein complexes in situ.

Moreira JM, Thorsen SB, Brünner N, Stenvang J.

Expert Rev Proteomics. 2013 Jun;10(3):219-21. doi: 10.1586/epr.13.22.

PMID:
23777212
3.

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Dupouy S, Doan VK, Wu Z, Mourra N, Liu J, De Wever O, Llorca FP, Cayre A, Kouchkar A, Gompel A, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8235-51.

4.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

5.

Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.

Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK.

Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):775-84.

PMID:
11697324
6.
7.

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.

Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G, Alaoui-Jamali MA.

Mol Biol Cell. 2002 Nov;13(11):4029-44.

8.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T.

J Pathol. 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Erratum in: J Pathol. 2013 May;230(1):e1.

PMID:
22262199
9.
10.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.

Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G.

J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0.

11.

The neuregulin-I/ErbB signaling system in development and disease.

Britsch S.

Adv Anat Embryol Cell Biol. 2007;190:1-65. Review.

PMID:
17432114
12.

Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.

Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, Rosemann M, Aubele M.

Mol Oncol. 2015 Jan;9(1):282-94. doi: 10.1016/j.molonc.2014.08.012.

13.

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO.

Breast Cancer Res Treat. 2014 May;145(1):33-44. doi: 10.1007/s10549-014-2925-7.

14.

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.

Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM.

Breast Cancer Res Treat. 2012 Apr;132(2):463-70. doi: 10.1007/s10549-011-1606-z.

PMID:
21638049
15.

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.

Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8252-69.

16.

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G.

Breast Cancer Res. 2008;10(1):R2. doi: 10.1186/bcr1843.

18.

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F.

Breast Cancer Res. 2010;12(3):R27. doi: 10.1186/bcr2575.

19.

ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.

Contessa JN, Abell A, Valerie K, Lin PS, Schmidt-Ullrich RK.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):851-8.

PMID:
16751066
20.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

Items per page

Supplemental Content

Support Center